These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 36563059)

  • 1. An integrated investigation of structural and pathway alteration caused by PIK3CA and TP53 mutations identified in cfDNA of metastatic breast cancer.
    R HC; Kumar S U; R G; Naayanan PJ; Sathiyarajeswaren P; Devi MSS; K SS; Doss C GP
    J Cell Biochem; 2023 Feb; 124(2):188-204. PubMed ID: 36563059
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma cell-free tumor DNA, PIK3CA and TP53 mutations predicted inferior endocrine-based treatment outcome in endocrine receptor-positive metastatic breast cancer.
    Chen TW; Hsiao W; Dai MS; Lin CH; Chang DY; Chen IC; Wang MY; Chang SH; Huang SM; Cheng AL; Wu KW; Tan KT; Lu YS
    Breast Cancer Res Treat; 2023 Oct; 201(3):377-385. PubMed ID: 37344660
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection of TP53/PIK3CA Mutations in Cell-Free Plasma DNA From Metastatic Breast Cancer Patients Using Next Generation Sequencing.
    Nakauchi C; Kagara N; Shimazu K; Shimomura A; Naoi Y; Shimoda M; Kim SJ; Noguchi S
    Clin Breast Cancer; 2016 Oct; 16(5):418-423. PubMed ID: 27265061
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical significance of gene mutation in ctDNA analysis for hormone receptor-positive metastatic breast cancer.
    Shibayama T; Low SK; Ono M; Kobayashi T; Kobayashi K; Fukada I; Ito Y; Ueno T; Ohno S; Nakamura Y; Takahashi S
    Breast Cancer Res Treat; 2020 Apr; 180(2):331-341. PubMed ID: 32020432
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutation profiling in the PIK3CA, TP53, and CDKN2A genes in circulating free DNA and impalpable breast lesions.
    Delmonico L; Costa MASM; Fournier MV; Romano SO; Nascimento CMD; Barbosa AS; Moreira ADS; Scherrer LR; Ornellas MHF; Alves G
    Ann Diagn Pathol; 2019 Apr; 39():30-35. PubMed ID: 30634138
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical significance of plasma cell-free DNA mutations in PIK3CA, AKT1, and ESR1 gene according to treatment lines in ER-positive breast cancer.
    Takeshita T; Yamamoto Y; Yamamoto-Ibusuki M; Tomiguchi M; Sueta A; Murakami K; Iwase H
    Mol Cancer; 2018 Feb; 17(1):67. PubMed ID: 29482551
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identifying Circulating Tumor DNA Mutation Profiles in Metastatic Breast Cancer Patients with Multiline Resistance.
    Hu ZY; Xie N; Tian C; Yang X; Liu L; Li J; Xiao H; Wu H; Lu J; Gao J; Hu X; Cao M; Shui Z; Xiao M; Tang Y; He Q; Chang L; Xia X; Yi X; Liao Q; Ouyang Q
    EBioMedicine; 2018 Jun; 32():111-118. PubMed ID: 29807833
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interplay between ESR1/PIK3CA codon variants, oncogenic pathway alterations and clinical phenotype in patients with metastatic breast cancer (MBC): comprehensive circulating tumor DNA (ctDNA) analysis.
    Gerratana L; Davis AA; Velimirovic M; Clifton K; Hensing WL; Shah AN; Dai CS; Reduzzi C; D'Amico P; Wehbe F; Medford A; Wander SA; Gradishar WJ; Behdad A; Puglisi F; Ma CX; Bardia A; Cristofanilli M
    Breast Cancer Res; 2023 Oct; 25(1):112. PubMed ID: 37784176
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical implications of genomic profiles in metastatic breast cancer with a focus on TP53 and PIK3CA, the most frequently mutated genes.
    Kim JY; Lee E; Park K; Park WY; Jung HH; Ahn JS; Im YH; Park YH
    Oncotarget; 2017 Apr; 8(17):27997-28007. PubMed ID: 28427202
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic role of PIK3CA mutations of cell-free DNA in early-stage triple negative breast cancer.
    Takeshita T; Yamamoto Y; Yamamoto-Ibusuki M; Inao T; Sueta A; Fujiwara S; Omoto Y; Iwase H
    Cancer Sci; 2015 Nov; 106(11):1582-9. PubMed ID: 26353837
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PIK3CA hotspot mutations p. H1047R and p. H1047L sensitize breast cancer cells to thymoquinone treatment by regulating the PI3K/Akt1 pathway.
    Zhou J; Imani S; Shasaltaneh MD; Liu S; Lu T; Fu J
    Mol Biol Rep; 2022 Mar; 49(3):1799-1816. PubMed ID: 34816327
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Circulating Tumor DNA Profiling From Breast Cancer Screening Through to Metastatic Disease.
    Page K; Martinson LJ; Fernandez-Garcia D; Hills A; Gleason KLT; Gray MC; Rushton AJ; Nteliopoulos G; Hastings RK; Goddard K; Ions C; Parmar V; Primrose L; Openshaw MR; Guttery DS; Palmieri C; Ali S; Stebbing J; Coombes RC; Shaw JA
    JCO Precis Oncol; 2021; 5():. PubMed ID: 34849446
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circulating tumor DNA profile and its clinical significance in patients with hormone receptor-positive and HER2-negative mBC.
    Tang Y; Li J; Liu B; Ran J; Hu ZY; Ouyang Q
    Front Endocrinol (Lausanne); 2022; 13():1075830. PubMed ID: 36518248
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cell-free DNA mutations as biomarkers in breast cancer patients receiving tamoxifen.
    Jansen MP; Martens JW; Helmijr JC; Beaufort CM; van Marion R; Krol NM; Monkhorst K; Trapman-Jansen AM; Meijer-van Gelder ME; Weerts MJ; Ramirez-Ardila DE; Dubbink HJ; Foekens JA; Sleijfer S; Berns EM
    Oncotarget; 2016 Jul; 7(28):43412-43418. PubMed ID: 27270325
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Somatic alterations of TP53, ERBB2, PIK3CA and CCND1 are associated with chemosensitivity for breast cancers.
    Yang L; Ye F; Bao L; Zhou X; Wang Z; Hu P; Ouyang N; Li X; Shi Y; Chen G; Xia P; Chui M; Li W; Jia Y; Liu Y; Liu J; Ye J; Zhang Z; Bu H
    Cancer Sci; 2019 Apr; 110(4):1389-1400. PubMed ID: 30776175
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical Utility of Circulating Cell-Free DNA Mutations in Anaplastic Thyroid Carcinoma.
    Qin Y; Wang JR; Wang Y; Iyer P; Cote GJ; Busaidy NL; Dadu R; Zafereo M; Williams MD; Ferrarotto R; Gunn GB; Wei P; Patel K; Hofmann MC; Cabanillas ME
    Thyroid; 2021 Aug; 31(8):1235-1243. PubMed ID: 33599171
    [No Abstract]   [Full Text] [Related]  

  • 17. ESR1 and PIK3CA mutational status in serum and plasma from metastatic breast cancer patients: A comparative study.
    Takeshita T; Yamamoto Y; Yamamoto-Ibusuki M; Tomiguchi M; Sueta A; Iwase H
    Cancer Biomark; 2018; 22(2):345-350. PubMed ID: 29689710
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of multiplex digital PCR assays for the detection of PIK3CA mutations in the plasma of metastatic breast cancer patients.
    Corné J; Le Du F; Quillien V; Godey F; Robert L; Bourien H; Brunot A; Crouzet L; Perrin C; Lefeuvre-Plesse C; Diéras V; De la Motte Rouge T
    Sci Rep; 2021 Aug; 11(1):17316. PubMed ID: 34453076
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relapsed and De Novo Metastatic HER2-positive Breast Cancer Treated With Trastuzumab: Tumor Genotypes and Clinical Measures Associated With Patient Outcome.
    Kotoula V; Tsakiri K; Koliou GA; Lazaridis G; Papadopoulou K; Giannoulatou E; Tikas I; Christodoulou C; Chatzopoulos K; Bobos M; Pentheroudakis G; Tsolaki E; Batistatou A; Kotsakis A; Koutras A; Linardou H; Razis E; Res E; Pectasides D; Fountzilas G
    Clin Breast Cancer; 2019 Apr; 19(2):113-125.e4. PubMed ID: 30545790
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutational landscape of pan-cancer patients with PIK3CA alterations in Chinese population.
    Huang Q; Zhou Y; Wang B; Zhao Y; Zhang F; Ding B
    BMC Med Genomics; 2022 Jul; 15(1):146. PubMed ID: 35778737
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.